ManiMNICF 98 EBITDA Margin % is 50.10% as of Feb. 2026, which is 28% above its 10-year median of 39.06. GuruFocus rates MNICF with a GF Score™ of 98/100 and a GF Value™ of $15.94. The stock has 6 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Mani ranks better than 94.12% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Mani's EBITDA for the
three
months ended in Feb. 2026 was $26.7 Mil. Mani's Revenue for the
three
months ended in Feb. 2026 was $53.4 Mil. Therefore, Mani's EBITDA margin for the quarter that ended in Feb. 2026 was 50.10%.
Mani (OTCPK:MNICF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Mani EBITDA Margin % Related Terms
Mani EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Mani's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MNICF vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Mani's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mani EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mani's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Mani's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mani (MNICF) has a EBITDA Margin % of 50.10% as of Feb. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Mani and its competitors. This is 28% above median its historical median of 39.06. Over the past decade, Mani's EBITDA Margin % has ranged from 31.79 to 53.28. According to the industry distribution chart, Mani ranks #48 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 5.9%.
Is Mani's EBITDA Margin % too high?
Mani's current EBITDA Margin % of 50.10% is 28% above median its 10-year median of 39.06. Over the past 10 years, this metric has ranged from a low of 31.79 to a high of 53.28. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Mani's value of 50.10% is 570.2% above this industry median. Based on the distribution chart, Mani ranks #48 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Mani has a GF Score™ of 98/100, reflecting its overall financial health beyond just this single metric.
How does Mani's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Mani ranks #48 out of 816 companies for EBITDA Margin %. This places Mani in the top 6% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Mani's value of 50.10% is 570.2% above this benchmark. Historically, Mani's own EBITDA Margin % has ranged from 31.79 to 53.28 over the past decade. While the company's 10-year median is 39.06 vs. the industry median of 7.48, Mani has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mani's current EBITDA Margin % of 50.10% is 570.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Mani and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mani's current EBITDA Margin % is 50.10%, which is 28% above median its own 10-year median of 39.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mani stock overvalued right now?
Mani (MNICF) has a current EBITDA Margin % of 50.10%. The stock's GF Value™ is $15.94, compared to a current price of $12.82 — trading 19.6% below its estimated fair value. The current EBITDA Margin % is 50.10%, which is 28% above median its 10-year median of 39.06 and 570.2% above the Medical Devices & Instruments industry median of 7.48. Mani's overall GF Score™ is 98/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Mani (MNICF), the current EBITDA Margin % is 50.10% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mani (MNICF) Overvalued in 2026?
Based on GuruFocus' analysis, Mani stock appears to be undervalued.
The current stock price of $12.82 is trading 19.6% below its estimated GF Value™ of $15.94.
Key valuation signals for MNICF:
EBITDA Margin %: 50.10% (28% above median its 10-year median of 39.06)
GF Value™: $15.94 vs. price of $12.82 (19.6% below fair value)
Industry Position: 570.2% above the Medical Devices & Instruments median (#48 of 816)
No single metric tells the full story. See the MNICF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mani Inc manufactures medical devices and dental instruments. It sells products in four categories: surgical instruments, ophthalmic instruments, suture needles, and dental instruments. Mani's surgical products include instruments such as staplers, vessel knives, and bone saws. Its ophthalmic instruments include a range of knives used during eye surgery and ophthalmic sutures. Mani's suture needles business includes a variety of taper point and cutting eyeless needles, which require suture attachment and sterilization by the customer, as well as stainless-steel eyed needles. The firm's dental instruments include endodontic instruments and accessories, root canal equipment, and finishing and polishing instruments.
98GF Score
Get the complete analysis for MNICF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNICF has been successfully added to your 
